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Abstract
Background: Over the last decades, the standard adjuvant chemotherapy for breast cancer changed 
various times, following the results of randomized controlled trials. The aim of the present study 
was to review the experience of our Unit, comparing three different regimens for breast cancer, 
used in subsequent years: CMF, protocols containing anthracyclines, and then taxanes, either in 
monotherapy or in combination with anthracyclines and/or trastuzumab.
Methods: We retrospectively analysed the results of 230 breast cancer patients operated on in our 
Unit between the year 2000 and 2017 and treated with adjuvant chemotherapy. The patients had 
mean follow-up of 60 months (Range 12 months to 192 months). Disease-free survival and toxicity 
were evaluated according to the adjuvant chemotherapy regimen used.
Results: The chemotherapy regimen used significantly influenced disease-free survival (p=0.02). The 
impact on relapse appeared comparable choosing either CMF scheme or anthracyclines. Whereas, 
taxane-containing regimens proved to be significantly protective against relapse (HR=0.33), by 
univariate Cox analysis (p=0.04). By multivariate analysis, the influence of adjuvant chemotherapy 
was even stronger (p=0.01) and taxane reduced dramatically the relapse risk (HR=0.26). The 
adjuvant chemotherapy regimen was a significant and independent prognostic factor for disease-
free interval. The superiority of taxane-based therapy, compared to anthracyclines and CMF, was 
evident also in triple-negative tumours, as 100% of patients were disease-free after 96 months of 
follow up. Concerning toxicity, taxane was the best tolerable regimen and significantly reduced 
hematological, gastrointestinal and cutaneous toxicity. In a separate analysis for HER2-positive 
tumours, 90% of the patients treated with trastuzumab were disease-free at 100 months follow up, 
in comparison with only 65% of HER2-positive women not undergoing this treatment.
Conclusions: Our study showed that taxane-containing regimens, either in combination with 
anthracyclines or in monotherapy, were the most effective and tolerable adjuvant chemotherapy 
for breast cancer. These results confirm the current literature knowledge about the effectiveness of 
taxanes as adjuvant treatment for breast cancer. In addition, our study also confirmed the value of 
trastuzumab as adjuvant therapy in HER2-positive women on disease-free survival.
Keywords: Breast cancer; Adjuvant chemotherapy; Taxanes; Anthracyclines; CMF; 
Trastuzumab; Toxicity
Introduction
Chemotherapy has represented the first systemic adjuvant therapy for breast cancer and 
it was introduced in the 1970’s. Since then, several randomized clinical trials aimed to compare 
polychemotherapy regimens and monochemotherapy and the results are collected in periodic meta-
analysis by EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Currently we know that, 
when chemotherapy is indicated after surgery, polychemotherapy is preferable as compared to a 
monotherapy, because of its superiority in terms of overall survival and disease-free survival [1].
It is possible to classify schematically three different generations of adjuvant chemotherapy 
regimens for breast cancer with progressive better results as regards outcomes like disease-free 
interval and overall survival [2]:
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•	 First-generation regimens: these mainly consists in CMF 
protocol (6 cycles to 12 cycles), a combination of cyclophosphamide, 
methotrexate and fluorouracil. This scheme is nowadays rarely used.
•	 Second-generation regimens: anthracyclines reduced 
mortality of 16% and risk of relapse of 11%, compared to CMF [2]. 
These regimens have an important toxicity, in particular cardiac (heart 
failure) and hematological (acute myeloid leukaemia) toxicities [3].
•	 Third-generation regimens: protocols containing either 
both anthracyclines and taxanes or taxanes in monotherapy. These 
schemes were introduced between 1990 and 2000 and reduced 
mortality of 14% and risk of relapse of 16% as compared to second-
generation regimens. They are given both in combined (TAC/
TEC) and sequential (AC/EC/FEC x 3-4 cycles followed by taxanes) 
schemes.
In tumours positive for HER2 (Human Epidermal Growth Factor 
Receptor 2), a one-year-long therapy (18 cycles) with recombined 
humanized monoclonal antibody trastuzumab is indicated [4-7]. 
If trastuzumab is given in combination with anthracyclines, it is 
necessary to monitor carefully and periodically cardiac function, 
because of the additional cardiac toxicity. However, the effect on 
heart of this antibody appears to be reversible, in literature studies [8].
The aim of the present study was to analyse the results in our 
unit between the years 2000 and 2017, comparing three different 
eras of adjuvant chemotherapy regimens for breast cancer: CMF 
regimen, anthracyclines-containing regimens, and taxanes either 
in monotherapy or in combination with anthracyclines and/or 
trastuzumab. 
Materials and Methods
We collected data of all patients operated on for invasive breast 
cancer and subsequently treated with adjuvant chemotherapy at our 
breast unit, between the year 2000 and 2017. As the chemotherapy 
regimen varied with time, we had the opportunity to compare the 
results of different protocols. The patients were followed for an 
average 60-months (Range 12 months to 192 months) with clinical 
breast examination every 6 months, mammography and breast 
ultrasound every 12 months. Any relapse (local, regional or distant) 
and disease-related death was recorded. We focused our attention 
on disease-free survival and toxicity. Overall, we had 230 patients 
with adequate follow up available. In addition, we identified two 
subgroups of patients: 69 women had HER2 positive tumors and 26 
patients with triple-negative tumours.
All the patients included in this analysis received adjuvant 
chemotherapy for a number of cycles adequate for each scheme. The 
patients received the following drugs and protocols: epirubicin and 
doxorubicin (anthracyclines), paclitaxel and docetaxel (taxanes), 
cyclophosphamide, vinorelbine, AC, TC, TCH, EC, CMF, and FEC.
Between two cycles of chemotherapy, each patient was checked 
by clinical examination and blood tests. Furthermore, cardiac 
function was regularly monitored by electrocardiography and 
echocardiography, because of the possible cardiac toxicity of some of 
these therapeutic regimens.
Toxicity was graded in accordance with the Common 
Figure 1: Kaplan-Meier Estimate of Disease-free Survival, choosing different 
adjuvant protocols.
Figure 2: Kaplan-Meier Estimate of Disease-free Survival, choosing different 
adjuvant protocols, in triple negative tumours subgroup.
Figure 3: Kaplan-Meier Estimate of Disease-free Survival in HER2-positive 
patients undergoing trastuzumab or not.
Figure 4: Drug-related main toxic effects due to different adjuvant 
chemotherapy.
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Terminology Criteria for Adverse Events version 4.0 and only grade 3 
to 4 events were considered in the subsequent analysis [9].
Disease-free survival was estimated by Kaplan-Meier method and 
the significance of the differences were evaluated by Log-Rank Test. 
Univariate and multivariate Cox analyses were performed to estimate 
the significance of the correlation among all the parameters in the 
study with regard to disease-free survival. All statistics were carried 
out with IBM SPSS for Windows, Version 20.
Results and Discussion
In the whole series of 230 patients, 57 women were treated with 
CMF scheme, 47 were given anthracyclines and 126 received taxanes 
either in monotherapy or in combination with anthracyclines. In 
addition, among the 69 patients with tumor positive for HER2 
receptor, 44 received monoclonal trastuzumab for 12 months, 
whereas 25 patients did not. Overall, the mean disease-free interval 
was 55 months, (Range 12 months to 192 months).
Disease-free survival was significantly higher in the taxanes group, 
as compared with CMF protocol and anthracyclines in monotherapy 
(p=0.02). After 100 months of follow up, roughly 63% of women 
treated with CMF or anthracyclines were free from disease, in 
comparison with 90% for patients receiving taxanes in monotherapy 
or in combination with anthracyclines (Figure 1). Taxanes proved 
to be particularly effective in the subpopulation with triple-negative 
tumours. In this sub-group 100% of patients were disease-free after 
96 months, vs. 50% of women receiving CMF or pure anthracyclines 
schemes (Figure 2). However, because of the limited number of 
patients, this result did not reach statistical significance (p=0.1).
In the sub-group of HER2-positive patients, 90% of women 
receiving trastuzumab were free from recurrence after 96 months of 
follow up, vs. 65% for the patients not receiving trastuzumab. Again, 
this striking difference did not reach the level of statistical significance 
because of the small sample in analysis (Figure 3).
By univariate Cox analysis, taxanes proved to be significantly 
protective against relapse (HR=0.33; p=0.04). Whereas, the impact 
on recurrence appeared to be comparable choosing either CMF 
scheme or anthracyclines (Table 1). By multivariate analysis, only 
three parameters resulted significant and independent predictors of 
recurrence: stage AJCC, type of adjuvant chemotherapy and triple 
negative tumours (Table 2). The superiority of protocols including 
taxanes in reducing the recurrence risk was even stronger when 
assessed in the multivariate model (HR=0.26; p=0.01). Therefore, 
the type of adjuvant chemotherapy turned out to be a significant and 
independent prognostic factor.
Concerning chemotherapy-related toxicity, among patients 
receiving the CMF scheme, the most frequent events were 
gastrointestinal (50.9%), cutaneous (mainly alopecia, 19.3%) 
and haematological (19.3%). Anthracyclines primarily caused 
gastrointestinal (40.4%), haematological (36.2%), cutaneous (21.3%) 
and cardiac (12.8%) toxic effects. Taxanes showed significantly 
lower toxicity, in particular as regards haematological (15.9%), 
gastrointestinal (19%) and cutaneous (alopecia, 1.6%) events 
(p<0.001) (Figure 4).
In the current study, reviewing our unit experience with adjuvant 
chemotherapy for breast cancer, we compared the results of three 
classic protocols that represented the standard in subsequent years: 
CMF, anthracyclines and then taxanes, in most recent years. This 
is a retrospective analysis and it has the obvious limitation of this 
study design. Nonetheless, we found that patients receiving taxanes-
containing regimens had a significantly better Disease-free survival 
(Figure 1). In addition, either by univariate or by multivariate Cox 
analysis, adjuvant treatment containing taxanes was associated 
with a significant reduction of recurrence risk. In particular, by 
multivariate Cox analysis we found that taxanes as adjuvant were 
associated with roughly a four-fold decrease of recurrence risk, as 
compared with the other regimens (HR=0.26; p=0.01). In addition, by 
multivariate analysis it was possible to assess that the type of adjuvant 
chemotherapy administered was a significant and independent 
prognostic factor in the current series. These results are in accordance 
with currently literature knowledge about effectiveness of taxanes 
in the adjuvant setting [2]. Recently, Watanabe et al., [10] reported 
results of a randomized clinical trial, which compared taxanes in 
monotherapy with a combination of taxanes and anthracyclines as 
adjuvant chemotherapy in women affected by breast cancer with 
lymph node involvement. In this specific subgroup of mammalian 
tumours, it was not possible to demonstrate taxanes monotherapy 
non-inferiority, so the association of anthracyclines use is still 
mandatory in this group of high risk patients [10]. Therefore, it is 
possible to state that combination of anthracyclines and taxanes 
is currently the most effective adjuvant chemotherapy for breast 
cancer. In addition, it was interesting to analyse disease-free survival 
according to type of chemotherapy treatment in the subgroup of 
triple negative tumours. Women with these tumours frequently 
have an unfavorable prognosis, firstly because of the lack of specific 
therapeutic tools to treat them, as pointed out by Sledge et al., [11] 
Furthermore, triple negative tumours often occur in premenopausal 
women and show aggressive behavior. At present, there is increasing 
interest for systemic platinum chemotherapy as treatment for these 
tumours [11]. We don’t have Platinum treated patients in this series. 
However, in our experience we found a benefit in using taxanes in 
triple negative tumours in comparison with former schemes: 100% of 
taxane-treated women were free from recurrence vs. 50% of patients 




















Not Triple Negative Tumour Ref.
0.03
Triple Negative Tumour 2.5
Table 2: Multivariate Cox analysis for disease-free survival, considering the 
interaction among three independent prognostic factors.
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up. Because of the limited number of patients with triple negative 
tumours in this analysis, our results were not statistically significant 
and the striking difference observed has to be interpreted with 
caution. It is interesting, however, that our findings are in accordance 
with data reported in a review of Whaba et al., [12] which focused on 
this specific issue.
It is also relevant that the known effectiveness of adjuvant therapy 
with trastuzumab, in HER2-positive tumours was confirmed in our 
data set [4,5,13]. Indeed, we found that 90% of women who received 
Trastuzumab were free from disease vs. 65% of patients not treated, 
after 96-months follow-up. Again, these results were not statistically 
significant because of the limited number of HER2-positive patients 
in our sample (Figure 3). Nonetheless, it is interesting to observe how, 
in the clinical practice, the introduction of Trastuzumab in more 
recent years has dramatically influenced the outcome of the patients 
with HER-2 positive breast cancer, even in our relatively small series.
With regard to toxic effects, in the current study taxanes allowed 
to reduce significantly gastrointestinal haematological and cutaneous 
toxicity, that occurred in 19%, 15.6% and 1.6%, of the patients, 
respectively, in comparison with CMF and pure anthracyclines 
regimens. Cardiac toxicity was, at a first glance, relatively high among 
patients receiving taxanes protocols (Figure 4). However, this possibly 
occurred because many patients in the taxanes group also received 
anthracyclines and trastuzumab. Therefore, it is likely that most of 
the cardiac toxicity events were due to these latter agents. Actually, 
anthracyclines cause important toxic effects, mainly haematological, 
gastrointestinal, cardiac and cutaneous (alopecia).
Conclusion
The review of our experience in adjuvant chemotherapy for breast 
cancer showed that the introduction of taxanes-containing protocols 
turned out to be safer and more effective in increasing disease-free 
survival. Therefore, our data in agreement with current literature 
knowledge, confirm that taxanes containing regimens, generally 
in combination with anthracyclines, should be considered the first 
choice chemotherapy in the adjuvant setting for breast cancer. In 
future studies it will be interesting to test the effectiveness of pure 
taxanes chemotherapy. Possibly this schedule could produce even 
greater safety with equal efficacy. Currently such studies are ongoing, 
as reported by Watanabe.
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